Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

被引：0

作者：

Hodi, F. Stephen

Chiarion-Sileni, Vanna

Lewis, Karl D.

Grob, Jean-Jacques

Rutkowski, Piotr

Lao, Christopher D.

Cowey, Charles Lance

Schadendorf, Dirk

Wagstaff, John

Dummer, Reinhard

Queirolo, Paola

Smylie, Michael

Butler, Marcus O.

Hill, Andrew Graham

Marquez-Rodas, Ivan

Haanen, John B. A. G.

Durani, Piyush

Wang, Peter

Wolchok, Jedd D.

Larkin, James

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] IOV IRCCS, Veneto Inst Oncol, Veneto, Italy

[3] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA

[4] Aix Marseille Univ, CHU Timone, Marseille, France

[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[6] Univ Michigan, Michigan Med, Rogel Canc Ctr, Ann Arbor, MI USA

[7] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA

[8] Univ Essen & German Canc Consortium, Essen, Germany

[9] Swansea Univ, Coll Med, Swansea, W Glam, Wales

[10] Univ Spital Zurich, Zurich, Switzerland

[11] IRCCS, European Inst Oncol, IEO, Milan, Italy

[12] Cross Canc Inst, Edmonton, AB, Canada

[13] Univ Hlth Network, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada

[14] Tasman Oncol Res Ltd, Southport, Qld, Australia

[15] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[16] Antonivan Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands

[17] Bristol Myers Squibb, Uxbridge, Middx, England

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Mem Sloan Kettering Canc Ctr, New York, NY USA

[20] Royal Marsden Hosp, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9522

引用

页数：1

共 50 条

[1] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Grob, Jean-Jacques
Rutkowski, Piotr
Lao, Christopher D.
Cowey, C. Lance
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Ferrucci, Pier Francesco
Smylie, Michael
Butler, Marcus O.
Hill, Andrew
Marquez-Rodas, Ivan
Haanen, John B. A. G.
Guidoboni, Massimo
Maio, Michele
Schoffski, Patrick
Carlino, Matteo S.
Lebbe, Celeste
McArthur, Grant
Ascierto, Paolo A.
Daniels, Gregory A.
Long, Georgina, V
Bas, Tuba
Ritchings, Corey
Larkin, James
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
[2] First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma
Turajlic, S.
Gore, M.
Larkin, J.
ANNALS OF ONCOLOGY, 2018, 29 (03) : 542 - 543
[3] Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Long, Georgina V.
Larkin, James
Schadendorf, Dirk
Grob, Jean-Jacques
Lao, Christopher D.
Marquez-Rodas, Ivan
Wagstaff, John
Lebbe, Celeste
Pigozzo, Jacopo
Robert, Caroline
Ascierto, Paolo A.
Atkinson, Victoria
Postow, Michael A.
Atkins, Michael B.
Sznol, Mario
Callahan, Margaret K.
Topalian, Suzanne L.
Sosman, Jeffrey A.
Kotapati, Srividya
Thakkar, Pratik K.
Ritchings, Corey
Benito, Melanie Pe
Re, Sandra
Soleymani, Samira
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (08)
[4] 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma
Larkin, J.
Sileni, V. Chiarion
Marqueste, C. Gaudy
Rutkowski, P.
Medina, T. M.
Lao, C. D.
Cowey, C. L.
Schadendorf, D.
Wagstaff, J.
Dummer, R.
Queirolo, P.
Walker, J.
Butler, M. O.
Hill, A. G.
Marquez-Rodas, I.
Haanen, J. B. A. G.
Nassar, A.
Askelson, M.
Hodi, F. S.
Wolchok, J. D.
ANNALS OF ONCOLOGY, 2024, 35 : 1234 - 1235
[5] Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
Timothy Baker
Helen Johnson
Srividya Kotapati
Andriy Moshyk
Melissa Hamilton
Murat Kurt
Victoria Federico Paly
PharmacoEconomics - Open, 2022, 6 : 697 - 710
[6] Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
Baker, Timothy
Johnson, Helen
Kotapati, Srividya
Moshyk, Andriy
Hamilton, Melissa
Kurt, Murat
Paly, Victoria Federico
PHARMACOECONOMICS-OPEN, 2022, 6 (05) : 697 - 710
[7] LONG-TERM SURVIVAL OF PATIENTS WITH ADVANCED MELANOMA TREATED SECOND LINE WITH IPILIMUMAB
Lee, D.
Pericleous, L.
Lebmeier, M.
Winn, B.
Batty, A.
Nikoglou, T.
ANNALS OF ONCOLOGY, 2012, 23 : 370 - 370
[8] First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
Gettinger, Scott
Rizvi, Naiyer
Chow, Laura
Borghaei, Hossein
Brahmer, Julie
Shepherd, Frances
Ready, Neal
Gerber, David
Antonia, Scott
Goldman, Jonathan W.
Juergens, Rosalyn
Geese, William
Young, Tina
L, Xuemei, I
Hellmann, Matthew
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S250 - S251
[9] 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO plus IPI) combination therapy in advanced melanoma
Larkin, J. M. G.
Chiarion-Sileni, V.
Gonzalez, R.
Grob, J. J.
Rutkowski, P.
Lao, C.
Cowey, C. L.
Schadendorf, D.
Wagstaff, J.
Dummer, R.
Ferrucci, P. F.
Smylie, M.
Hogg, D.
Hill, A.
Marquez-Rodas, I.
Haanen, J. B. A. G.
Rizzo, J.
Balogh, A.
Hodi, F. S.
Wolchok, J.
ANNALS OF ONCOLOGY, 2019, 30 : 904 - 905
[10] CheckMate 067: Long-term outcomes in patients with mucosal melanoma.
Shoushtari, Alexander Noor
Wagstaff, John
Ascierto, Paolo Antonio
Butler, Marcus O.
Lao, Christopher D.
Marquez-Rodas, Ivan
Chiarion-Sileni, Vanna
Dummer, Reinhard
Ferrucci, Pier F.
Lorigan, Paul
Smylie, Michael
van Dijck, Wim
Rizzo, Jasmine I.
Hodi, F. Stephen
Larkin, James M. G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →